Endovascular denervation combined with renal sympathetic denervation for treating uncontrolled drug-treated hypertension with type 2 diabetes: A case report

Uncontrolled drug-treated hypertension can lead to serious cardiovascular and cerebrovascular events. Type 2 diabetes mellitus has caused a huge health burden worldwide, with the global prevalence of chronic hyperglycemia or diabetes being approximately 1 in 11 among adults. Even in patients who are compliant with medication treatment and lifestyle changes, glycemic control may still be inadequate. In this case report, a young Chinese patient with uncontrolled drug-treated hypertension and type 2 diabetes was successfully treated with endovascular denervation combined with renal sympathetic denervation under three-dimensional guidance through the Ensite Velocity 5.0 system. The positive results from this study provide new opportunities for the treatment of uncontrolled drug-treated hypertension with type 2 diabetes.
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: Executive summary: A report of the American college of cardiology/ American Heart Association task force on clinical practice guidelines. Circulation. 2018;138:e426-e483. doi: 10.1161/CIR.0000000000000597
- Blood Pressure Lowering Treatment Trialists Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: An individual participant-level data meta-analysis. Lancet. 2021;397:1625-1636. doi: 10.1016/S0140-6736(21)00590-0
- Blood Pressure Lowering Treatment Trialists Collaboration. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: An individual participant-level data meta-analysis. Lancet. 2021;398:1053-1064. doi: 10.1016/S0140-6736(21)01921-8
- Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 2016;387:957-967. doi: 10.1016/S0140-6736(15)01225-8
- Kario K, Hoshide S, Narita K, Okawara Y, Kanegae H, Investigators n. Cardiovascular prognosis in drug-resistant hypertension stratified by 24-hour ambulatory blood pressure: The JAMP study. Hypertension. 2021;78:1781-190. doi: 10.1161/HYPERTENSIONAHA.121.18198
- Osborn JW, Tyshynsky R, Vulchanova L. Function of renal nerves in kidney physiology and pathophysiology. Annu Rev Physiol. 2021;83:429-450. doi: 10.1146/annurev-physiol-031620-091656
- Schmieder RE. Renal denervation: Where do we stand and what is the relevance to the nephrologist? Nephrol Dial Transplant. 2022;37:638-644. doi: 10.1093/ndt/gfaa237
- Bohm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): A multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444-1451. doi: 10.1016/S0140-6736(20)30554-7
- Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): A randomised, sham-controlled trial. Lancet. 2022;399:1401-1410. doi: 10.1016/S0140-6736(22)00455-X
- Barbato E, Azizi M, Schmieder RE, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC council on hypertension and the European association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2023;44:1313-1330. doi: 10.1093/eurheartj/ehad054
- Pan T, Li L, Wei Q, et al. Endovascular celiac denervation for glycemic control in patients with type 2 diabetes mellitus. J Vasc Interv Radiol. 2021;32:1519.e2-1528.e2. doi: 10.1016/j.jvir.2021.07.023
- Mobinizadeh M, Arabloo J, Hamouzadeh P, Akbari Sari A. A systematic review of the effectiveness of catheter ablation NavX mapping system for treatment of the cardiac arrhythmia. Med J Islam Repub Iran. 2015;29:189.
- Khongphatthanayothin A, Kosar E, Nademanee K. Nonfluoroscopic three-dimensional mapping for arrhythmia ablation: Tool or toy? J Cardiovasc Electrophysiol. 2000;11:239-243. doi: 10.1111/j.1540-8167.2000.tb01792.x
- Hindricks G, Weiner S, McElderry T, et al. Acute safety, effectiveness, and real-world clinical usage of ultra-high density mapping for ablation of cardiac arrhythmias: Results of the TRUE HD study. Europace. 2019;21:655-661. doi: 10.1093/europace/euy191
- Kawakami T, Saito N, Yamamoto K, et al. Zero-fluoroscopy ablation for cardiac arrhythmias: A single-center experience in Japan. J Arrhythm. 2021;37:1488-1496. doi: 10.1002/joa3.12644